• GSK reported Q3 2026 sales of £8.9 billion, up 5%; core operating profit rose 5% to £3.1 billion.
• Specialty Medicines sales increased 15% to £3.9 billion; vaccine sales fell 2% to £2.6 billion.
• General Medicines sales held steady at £2.4 billion; total earnings per share fell 21% to 38.5p.
• Core earnings per share rose 1% to 54.6p; the dividend was 17p per share.
• Hibsago secured US and Japanese approvals; US regulators also cleared Jemperli for rectal cancer and Jideytro for lung cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GSK plc published the original content used to generate this news brief on October 28, 2026, and is solely responsible for the information contained therein.